Proven Solutions ImprovedSM
Tosk’s is a dynamic drug development company dedicated to alleviating the painful, debilitating, and potentially fatal side effects of front line cancer therapies and to make certain cancer drugs effective in patients who do not currently benefit from treatment. We are developing a family of what we call CompanionTM drugs that, when administered alongside certain cancer therapies, such as methotrexate, doxorubicin, cisplatin, EGFR inhibitors, and radiation — what we call parent therapies — will significantly improve patient outcomes. In other words, "PROVEN SOLUTIONS IMPROVEDTM".
As anyone who has had cancer, or had a family member with cancer, knows, the side effects of treatment can often be more debilitating than the disease itself. Also, side effects can limit dosing of cancer fighting treatments to less than would otherwise be desirable. And treating the symptoms of side effects can be costly, sometimes more expensive than the cancer treatment itself. Often, doctors, and patients, are faced with the question, “is the treatment worse than the disease itself?”
Tosk’s scientists have worked for a decade to develop an innovative, cost effective technology that uses the common fruit fly as a model for human diseases. These efforts evolved into two proprietary drug discovery platforms that use fruit flies as a tool to discover new, inexpensive, small molecule drugs. We call the approach Optimizing Marketed DrugsSM because it is used to enhance the effectiveness and safety of widely used chemotherapies and radiation treatment.
Our goal is to improve the quality of life of the millions of people around the globe suffering from cancer. We have patented two new drugs and have two more in development. Our first drug, TK-90, which addresses mucositis, the painful inflammation and ulceration of the mucous membranes lining the digestive tract, is undergoing clinical trials. Our second drug, TK-39, targets the side effects of certain cancer drugs that can permanently weaken the heart. Clinical trials for TK-39 are anticipated in 2018. Both drugs have performed well in the lab, and we expect will prove effective in human trials.
Another of our other drug development efforts addresses a barrier to cancer treatment that affects up to 40 percent of patients. These are patients with a genetic trait called oncogenic kRAS, which renders certain cancer drugs ineffective.
Our fourth initiative addresses the kidney toxicity and associated pain and hearing loss of a widely used class of cancer drugs.
Our mission inspires a dedicated and highly experienced staff, led by biotech veterans who have founded previous, successful medical products companies. The group includes highly respected research VPs with more than 20 years of industry experience, who guide the Company’s drug development efforts using Tosk proprietary discovery methods.